Abstract
The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and survival, in physiological as well as in pathological conditions (e.g., cancer). Indeed, they are so interconnected that, in a certain sense, they could be regarded as a single, unique pathway. In this paper, after a general overview of the biological significance and the main components of these pathways, we address the present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench.
| Original language | English |
|---|---|
| Article number | Article 64 |
| Journal | Frontiers in Oncology |
| Volume | 4 APR |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Akt
- Everolimus
- Inhibitors
- MTOR
- Novel agents
- PI3K
- Ridaforolimus
- Temsirolimus
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Targeting PI3K/Akt/mTOR signaling in cancer. / Porta, Camillo; Paglino, Chiara; Mosca, Alessandra.
In: Frontiers in Oncology, Vol. 4 APR, Article 64, 2014.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Targeting PI3K/Akt/mTOR signaling in cancer
AU - Porta, Camillo
AU - Paglino, Chiara
AU - Mosca, Alessandra
PY - 2014
Y1 - 2014
N2 - The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and survival, in physiological as well as in pathological conditions (e.g., cancer). Indeed, they are so interconnected that, in a certain sense, they could be regarded as a single, unique pathway. In this paper, after a general overview of the biological significance and the main components of these pathways, we address the present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench.
AB - The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and survival, in physiological as well as in pathological conditions (e.g., cancer). Indeed, they are so interconnected that, in a certain sense, they could be regarded as a single, unique pathway. In this paper, after a general overview of the biological significance and the main components of these pathways, we address the present status of the development of specific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds that are just leaving the laboratory bench.
KW - Akt
KW - Everolimus
KW - Inhibitors
KW - MTOR
KW - Novel agents
KW - PI3K
KW - Ridaforolimus
KW - Temsirolimus
UR - http://www.scopus.com/inward/record.url?scp=84901008792&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901008792&partnerID=8YFLogxK
U2 - 10.3389/fonc.2014.00064
DO - 10.3389/fonc.2014.00064
M3 - Article
VL - 4 APR
JO - Frontiers in Oncology
JF - Frontiers in Oncology
SN - 2234-943X
M1 - Article 64
ER -